|
1
|
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
|
J Clin Oncol
|
2006
|
6.55
|
|
2
|
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
|
Lancet Oncol
|
2013
|
4.30
|
|
3
|
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
|
J Clin Oncol
|
2009
|
4.05
|
|
4
|
Severe acute interstitial pneumonia and gefitinib.
|
Lancet
|
2003
|
3.94
|
|
5
|
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
|
J Clin Oncol
|
2008
|
1.88
|
|
6
|
Frequency of and variables associated with the EGFR mutation and its subtypes.
|
Int J Cancer
|
2010
|
1.79
|
|
7
|
Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction.
|
J Immunol
|
2002
|
1.39
|
|
8
|
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.
|
Cancer Res
|
2002
|
1.22
|
|
9
|
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer.
|
Clin Cancer Res
|
2012
|
1.12
|
|
10
|
Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.
|
Mol Ther
|
2005
|
1.08
|
|
11
|
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
|
Lung Cancer
|
2013
|
1.05
|
|
12
|
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
|
J Thorac Oncol
|
2014
|
1.04
|
|
13
|
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
|
J Thorac Oncol
|
2011
|
1.03
|
|
14
|
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
|
Cancer Res
|
2004
|
1.01
|
|
15
|
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
|
Oncologist
|
2012
|
0.98
|
|
16
|
Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
|
Clin Cancer Res
|
2005
|
0.93
|
|
17
|
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
|
Oncology
|
2011
|
0.92
|
|
18
|
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.
|
Lung Cancer
|
2013
|
0.87
|
|
19
|
Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice.
|
Int J Cancer
|
2005
|
0.87
|
|
20
|
Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
|
J Thorac Oncol
|
2014
|
0.83
|
|
21
|
Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
|
Intern Med
|
2015
|
0.83
|
|
22
|
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
|
J Pathol
|
2014
|
0.83
|
|
23
|
Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas.
|
Cancer Gene Ther
|
2002
|
0.81
|
|
24
|
Usefulness of linezolid in the treatment of hospital-acquired pneumonia caused by MRSA: a prospective observational study.
|
J Infect Chemother
|
2011
|
0.81
|
|
25
|
Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells.
|
Blood
|
2002
|
0.80
|
|
26
|
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
|
Oncologist
|
2013
|
0.79
|
|
27
|
Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model.
|
Cancer Gene Ther
|
2004
|
0.78
|
|
28
|
Acute-onset sarcoidosis with erythema nodosum and polyarthralgia (Löfgren's syndrome) in Japan: a case report and a review of the literature.
|
Intern Med
|
2006
|
0.78
|
|
29
|
N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers.
|
Oncogene
|
2003
|
0.78
|
|
30
|
[Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
|
Nihon Naika Gakkai Zasshi
|
2014
|
0.77
|
|
31
|
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
|
Expert Opin Pharmacother
|
2015
|
0.77
|
|
32
|
Cigarette smoking and lung cancer risk according to histologic type in Japanese men and women.
|
Cancer Sci
|
2013
|
0.77
|
|
33
|
Suppression of peritoneal implantation of gastric cancer cells by adenovirus vector-mediated NK4 expression.
|
Cancer Gene Ther
|
2005
|
0.77
|
|
34
|
A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.76
|
|
35
|
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
|
Respir Investig
|
2012
|
0.76
|
|
36
|
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
|
Cancer Sci
|
2008
|
0.75
|
|
37
|
[NK4 gene therapy].
|
Nihon Rinsho
|
2002
|
0.75
|
|
38
|
[A case of pulmonary Langerhans cell histiocytosis discovered by CT mass screening and followed by bronchoalveolar lavage].
|
Nihon Kokyuki Gakkai Zasshi
|
2006
|
0.75
|
|
39
|
[Necessary clinical laboratory tests for early diagnosis of severe pulmonary diseases].
|
Nihon Naika Gakkai Zasshi
|
2005
|
0.75
|
|
40
|
[Anti-RANKL antibody].
|
Nihon Rinsho
|
2015
|
0.75
|
|
41
|
Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues.
|
Int J Biol Markers
|
2015
|
0.75
|